BARBARA BOLEK: Open Payments
NPI 1629497748 · LOCKHART, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,266 in 67 payments from 18 companies in 2025. Trend: 2023 $585 · 2024 $795 · 2025 $1,266
Food & beverage: $1,266
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 7 | $241 |
| ABBVIE INC. | 22 | $226 |
| Novo Nordisk Inc | 8 | $186 |
| AstraZeneca Pharmaceuticals LP | 7 | $162 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $69 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| Abbott Laboratories | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
Products named: VRAYLAR, AIRSUPRA, JARDIANCE, Rybelsus, ZEPBOUND, REXULTI, Ozempic, Auvelity.
Industry payments across TX — which companies pay providers there.
